117 related articles for article (PubMed ID: 22037908)
1. Hormone therapy and ovarian borderline tumors: a national cohort study.
Mørch LS; Løkkegaard E; Andreasen AH; Kjær SK; Lidegaard Ø
Cancer Causes Control; 2012 Jan; 23(1):113-20. PubMed ID: 22037908
[TBL] [Abstract][Full Text] [Related]
2. Hormone therapy and different ovarian cancers: a national cohort study.
Mørch LS; Løkkegaard E; Andreasen AH; Kjaer SK; Lidegaard O
Am J Epidemiol; 2012 Jun; 175(12):1234-42. PubMed ID: 22517811
[TBL] [Abstract][Full Text] [Related]
3. Hormone therapy and ovarian cancer.
Mørch LS; Løkkegaard E; Andreasen AH; Krüger-Kjaer S; Lidegaard O
JAMA; 2009 Jul; 302(3):298-305. PubMed ID: 19602689
[TBL] [Abstract][Full Text] [Related]
4. Menopausal hormone therapy and ovarian cancer risk in the National Institutes of Health-AARP Diet and Health Study Cohort.
Lacey JV; Brinton LA; Leitzmann MF; Mouw T; Hollenbeck A; Schatzkin A; Hartge P
J Natl Cancer Inst; 2006 Oct; 98(19):1397-405. PubMed ID: 17018786
[TBL] [Abstract][Full Text] [Related]
5. Hormone therapy and the impact of estrogen intake on the risk of ovarian cancer.
Glud E; Kjaer SK; Thomsen BL; Høgdall C; Christensen L; Høgdall E; Bock JE; Blaakaer J
Arch Intern Med; 2004 Nov; 164(20):2253-9. PubMed ID: 15534163
[TBL] [Abstract][Full Text] [Related]
6. Risk factors for epithelial borderline ovarian tumors: results of a Swedish case-control study.
Riman T; Dickman PW; Nilsson S; Correia N; Nordlinder H; Magnusson CM; Persson IR
Gynecol Oncol; 2001 Dec; 83(3):575-85. PubMed ID: 11733975
[TBL] [Abstract][Full Text] [Related]
7. Hormone replacement therapy in Denmark, 1995-2004.
Løkkegaard E; Lidegaard O; Møller LN; Agger C; Andreasen AH; Jørgensen T
Acta Obstet Gynecol Scand; 2007; 86(11):1342-51. PubMed ID: 17963062
[TBL] [Abstract][Full Text] [Related]
8. Menopausal hormones and risk of ovarian cancer.
Moorman PG; Schildkraut JM; Calingaert B; Halabi S; Berchuck A
Am J Obstet Gynecol; 2005 Jul; 193(1):76-82. PubMed ID: 16021062
[TBL] [Abstract][Full Text] [Related]
9. Ovarian cancer risk in postmenopausal women using estradiol-progestin therapy - a nationwide study.
Koskela-Niska V; Lyytinen H; Riska A; Pukkala E; Ylikorkala O
Climacteric; 2013 Feb; 16(1):48-53. PubMed ID: 22640598
[TBL] [Abstract][Full Text] [Related]
10. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women.
Colditz GA; Hankinson SE; Hunter DJ; Willett WC; Manson JE; Stampfer MJ; Hennekens C; Rosner B; Speizer FE
N Engl J Med; 1995 Jun; 332(24):1589-93. PubMed ID: 7753136
[TBL] [Abstract][Full Text] [Related]
11. Prognostic characteristics of breast cancer among postmenopausal hormone users in a screened population.
Kerlikowske K; Miglioretti DL; Ballard-Barbash R; Weaver DL; Buist DS; Barlow WE; Cutter G; Geller BM; Yankaskas B; Taplin SH; Carney PA
J Clin Oncol; 2003 Dec; 21(23):4314-21. PubMed ID: 14645420
[TBL] [Abstract][Full Text] [Related]
12. Hormone replacement therapy and cancer.
Gynecol Endocrinol; 2001 Dec; 15(6):453-65. PubMed ID: 11826770
[TBL] [Abstract][Full Text] [Related]
13. Controversial issues in climacteric medicine II. Hormone replacement therapy and cancer. International Menopause Society Expert Workshop. 9-12 June 2001, Opera del Duomo, Pisa, Italy.
Genazzani AR; Gadducci A; Gambacciani M
Climacteric; 2001 Sep; 4(3):181-93. PubMed ID: 11588941
[TBL] [Abstract][Full Text] [Related]
14. A prospective study of postmenopausal hormone use and ovarian cancer risk.
Danforth KN; Tworoger SS; Hecht JL; Rosner BA; Colditz GA; Hankinson SE
Br J Cancer; 2007 Jan; 96(1):151-6. PubMed ID: 17179984
[TBL] [Abstract][Full Text] [Related]
15. Risk for borderline ovarian tumours after exposure to fertility drugs: results of a population-based cohort study.
Bjørnholt SM; Kjaer SK; Nielsen TS; Jensen A
Hum Reprod; 2015 Jan; 30(1):222-31. PubMed ID: 25376453
[TBL] [Abstract][Full Text] [Related]
16. Postmenopausal hormone replacement therapy and risk of acute pancreatitis: a population-based case-control study.
Tetsche MS; Jacobsen J; Nørgaard M; Baron JA; Sørensen HT
Am J Gastroenterol; 2007 Feb; 102(2):275-8. PubMed ID: 17311649
[TBL] [Abstract][Full Text] [Related]
17. Estrogen replacement therapy following oophorectomy in women with a family history of ovarian cancer.
Eltabbakh GH; Piver MS; Hempling RE; Recio FO; Aiduk C
Gynecol Oncol; 1997 Jul; 66(1):103-7. PubMed ID: 9234929
[TBL] [Abstract][Full Text] [Related]
18. Breast cancer risk with postmenopausal hormonal treatment.
Collins JA; Blake JM; Crosignani PG
Hum Reprod Update; 2005; 11(6):545-60. PubMed ID: 16150813
[TBL] [Abstract][Full Text] [Related]
19. Body mass and endometrial cancer risk by hormone replacement therapy and cancer subtype.
McCullough ML; Patel AV; Patel R; Rodriguez C; Feigelson HS; Bandera EV; Gansler T; Thun MJ; Calle EE
Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):73-9. PubMed ID: 18187388
[TBL] [Abstract][Full Text] [Related]
20. Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study.
Canonico M; Fournier A; Carcaillon L; Olié V; Plu-Bureau G; Oger E; Mesrine S; Boutron-Ruault MC; Clavel-Chapelon F; Scarabin PY
Arterioscler Thromb Vasc Biol; 2010 Feb; 30(2):340-5. PubMed ID: 19834106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]